The aim of this study was to assess the outcome of patients with aplastic anemia (AA), receiving rabbit anti-thymocyte globulin (Thymoglobulin, SANOFI) and cyclosporin, as first line treatment. (range 1-84). Mortality within 90 days was 5.7% and 2.4%, respectively in the two time periods (P 5 .007).The actuarial 10-year survival for the entire population was 70%; transplant free survival was 64%. Predictors of survival in multivariate analysis, were severity of the disease, patients age and the interval between diagnosis and treatment. Survival was 87% vs 61% for responders at 6 months versus nonresponders (P < .0001). The 10-year survival of nonresponders at 6 months, undergoing a subsequent transplant (n 5 110), was 64%, vs 60% for patient not transplantated (n 5 266) (P 5 .1). The cumulative incidence of response was 37%, 52%, 65% respectively, at 90, 180, and 365 days. In multivariate analysis, negative predictors of response at 6 months, were older age, longer interval diagnosis treatment, and greater severity of the disease. In conclusion, early mortality is low after first line treatment of AA with Thymoglobulin, and has been further reduced after year 2008. Patients age, together with interval diagnosis-treament and severity of the disease, remain strong predictors of response and survival.
6 months. 11, 12 In addition, improved response rates with horse ATG, were driven mainly by studies with non-Asian patients.
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The aim of the present study was to assess the outcome of a large number of patients, treated in Europe and in Asia with Thymoglobuline and CsA first line, in the past decade. 22 because of lack of follow up data, and this left 955 patients evaluable for survival and 800 evaluable for response ( 
| M E TH ODS

| Study design
| Response
Response was defined as complete (CR) with the following peripheral blood counts: Hb >120 gr/L, Platelets >100 3 10 with response at fixed time points were considered responders at that time point. If data at specific time points were not available, the day of last transfusion after treatment, was used as cut off for response evaluation. These patients were classified as PR .
| Comparison with retrospective data
To compare the outcome of patients in this study with patients reported in the prospective EBMT study comparing Thymoglobulin and lymphoglobulin, 4 we selected only adults from the total number of patients: there were 558 adults aged 18-84 years, with a proportion of very severe, severe and non severe AA of 28%, 45%, 27%.
| Statistical analysis
The 3 | R E SU LTS
| Early mortality
The number of patients who died within 90 days from treatment was 39 (4%), whereas 167 died beyond day 190 (17%). Causes of death were hemorrhage (n 5 7), unspecified infections (n 5 28) and fungal infections (n 5 4). Early mortality <90 days, was age dependent: 1,9%, years as follows: 3.07% to 0.8%, 3.85% to 0.9%, 5.0% to 4.7%, 22% to 9%, respectively. Early mortality correlated with severity of the disease, and was higher in patients with very severe AA (7%) as compared to patients with severe or non severe AA (3%) (P 5 .006).
| Late mortality
Fiftyeight patients died between 91 -365 days, and 109 patients died beyond one year. In the first year mortality rates were similar between nontransplant and transplanted patients (6,9% vs 4,4%, P 5 .1). Between 1 and 2 years mortality was 3.4% vs 10.8%, respectively for nontransplanted and transplanted patients (P < .01). Between 2 and 5 years, mortality was 3,9% vs 9,1% (P 5 .004); beyond 5 years from ATG, mortality was 1,7% for not transplanted vs 2.8% for transplanted patients (P 5 .1).
| Response to treatment
Eight hundred patients were evaluable for response . The cumulative incidence of response (CI), which included complete and partial responses, at 90 days was 37% (95% CI 33-40%); at 180 days it was 52% (95% CI 48-55%) and at 365 days it was 65% (95% CI 61-68%).
The CI of the competing event (death) in the 3 time periods was respectively 5% (95% CI 3-6%), 11% (95% CI 9-13%) and 17% (95% CI 14-20%). The probability of response at 6 months was 52% in the 2 time periods (2008>). Of 464 nonresponders on day 190, 27% were classified as responders on day 1180, and 46% at day 1365.
The strongest predictor of response at 6 months was the interval diagnosis-treatment, 0-30 or >30 days from diagnosis: the response was respectively 62% and 54% (Greys test 0.05). The second prognostic factor was the age group (0-20, 21-40, 41-60, >60 years) with response at 6 months of 55%, 52%, 47% and 38% (P 5 .06 Greys test).
Severity of the disease had an impact on response but not significant (P 5 .1). The dose of ATG was stratified in 3 groups <52.5 mg/kgx5
(n 5 253), 2.5-3.5 mg/kg 3 5 (n 5 278) and 5>3.75 mg/kgx5
(n 5 424), 3.75 mg/kg being the canonical Thymoglobulin dose: the response rate at 6 months in patients <20 years of age, was 56%, 60%, 67% (P 5 .1) for the 3 doses; in adults over 20 years of age the response at 6 months was 58%, 42%, 69% respectively (P < .001).
| Relapse
Relapse was reported in 16% of responding patients: their survival at 10 years is 57%; it was 59% for patients receiving a second course of ATG and 69% for patients receiving a transplant (P 5 .5) was not predictive (RR 5 1.16, P 5 .6), and (d) only patients over the age of 60 had an increased risk of death (RR 2.8, P 5 .002).
| Second line treatment
| Univariate analysis on survival
With a median follow up of 1416 days (range 1-5420), the overall survival at 10 years, for all 955 patients, is 70% (Figure 1) , and 76% when patients were censored as surviving at the time of transplant. The following variables were strong pretreatment predictors of survival in univariate analysis: 1 patients age, with a 10-year survival of 80%, 70%, 49%, 38% of patients in the age group 0-20, 21-40, 41-60, and over 61% for nonresponders at 6 months (P < .0001) ( Figure 2C ). Because of the high survival of 376 nonresponders at 6 months, we further investigated the role of allogeneic HSCT: survival was 64% for 110 patients allografted and 60% for patients receiving a second course of ATG or supportive care untill response (n 5 266) (P 5 .1) ( Figure 2D ).
| Multivariate analysis on survival
In multivariate analysis, factors predicting overall survival were as follows ( Table 2) were not significant predictors of survival, although the death risk ratio was 0.77 for the most recent period of treatment (Table 2 ).
| Causes of death
The major cause of death was infections, overall 12%, followed by hemorrhages (2.6%). Transplant related causes of death included GvHD and graft rejection, accounting for 10% of transplant patients. In 12 cases the cause of death was acute myeloid leukemia (1.3%).
| D ISC USSION
This is a large retrospective study on patients with acquired AA treated first line with Thymoglobuine and CsA, addressing 4 major issues: early mortality, response rates, second line treatment, and survival. In the present study, the overall early mortality was 6% for patients treated [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] , and 2% in the period 2009-2012. This is true for all age groups, with current mortality within 90 days, ranging from 1.6%, for patients aged 1-59 years, to 9% for patients over 60:
the reduction in the latter group is particularly significant (22% to 9%,) .
In other words the current risk of early death, within the first 3 months, for patients treated first line with Thymoglobulin and CsA, is less than 2%, for younger patients (60 years), and 9% above 60 years of age.
The use of a lower dose of Thymoglobulin, was not associated with reduced toxicity. There were only 30 patients above the age of 70:
their overall early mortality is 33%, suggesting caution in the use of Thymoglobulin and CsA, in this elderly population. Causes of early death were mainly infectious: we did not collect data on the use of G-CSF, which has been reported to reduce infectious complications after treatment with horse ATG, 14 and we can not therefore comment on its use after first line rabbit ATG. However, it should be pointed out that mortality was not reduced in the EBMT randomized study. 14 Response was recorded in 800 patients: response at 6 months was 52% which compares favorably with the 40% response in the EBMT study on 35 patients 4 and 37% response in the NIH study on 60 patients. 3 The major predictor of response was the interval between diagnosis and treatment, best response being achieved in patients treated within 1 month from diagnosis. The dose of Thymoglobulin seems to have an effect, with best responses seen in both children and adults, receiving the classic dose of 3.75 mg/kg/day 3 5 days, but a randomized study comparing 2.5 mg/kg/day vs 3.75 mg/kg/day is ongoing in Asia, and will answer this question. Response at 6 months was, as expected, a strong predictor of survival, with 10-year survival of 96% for complete responders, 72% for partial responders and 61%
for nonresponders. We were particularly surprised with the 10-year survival of 61% for patients classified as nonresponders at 6 months, and we hypothesized that transplantation may have been the main salvage therapy. We thus compared 10-year survival of nonresponders at 6 months, receiving an allogeneic HSCT (n 5 110), with survival of patients not allografted (n 5 266), and found it was comparable: 64% for HSCT and 60% for patients receiving a second immunosuppressive treatment, or supportive care untill response. Because response was available in only 800 patients, and we had studied the effect of transplantation in patients classified as nonresponders at 6 months, we also Survival was the primary end point of this study, since we were concerned with results of two prospective studies showing rather poor two year survival of patients receiving Thymoglobulin, in the order of 60%, significantly less when compared to horse ATG, in the order of 80%. 3, 4 However, some retrospective studies had shown more promising results in first and second line treatment with rabbit ATG. [7] [8] [9] [10] 15 In the present study on 955 patients, the overall survival at 10 years was 70%, 76% after censoring patients as surviving at the time of transplant, and transplant free survival was 64%. When looking at predictors, we found 3 major significant variables: patients age, interval between diagnosis and treatment, and severity of the disease. These variable have already been shown to predict outcome in patients receiving ATG. 16, 17 We could not show an effect on survival of different schedules of Thymoglobulin, ranging from 2.5 mg/kg/day 35 to 3.75 mg/kg/day 35, although the latter regimen had a greater proportion of responders both in patients under the age of 20 years, as well as in older patients.
Finally, we compared the adult population from this data base (n 5 558), with 35 patients of the prospective EBMT study, receiving Thymoglobulin first line: the two groups were comparable for age (median 37) and severity of the disease, with an excess of very severe AA in the current larger study. The cumulative incidence of response at 6 months, was 40% in the EBMT study 4 and 58% in the adults of our study. Survival at 2 years was 68% in the EBMT study and 81% in the current study. It is difficult to explain why results should be different:
the number of patients could be one issue, since the EBMT study was based only on 35 patients receiving rabbit ATG. Also a recent meta- analysis on 1636 patients, shows no difference in survival between patients receiving horse or rabbit ATG.
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In conclusion, this study suggests that first line treatment of AA with Thymoglobulin is currently associated with a low early mortality within 90 days: for patients above 60 years, and especially above 70 years of age, early infectious complications suggest caution. Response rates at 6 months seem higher, compared to what as been reported in two prospective trials, but still somewhat lower than responses at 6 months with horse ATG: it may be that responses after rabbit ATG are delayed. This is confirmed by the fact that survival of nonresponders at 6 months, is comparable in patients receiving or not an allogeneic transplant. In consideration of the exciting results reported with the triple combination of horse ATG, CSA and eltrombopag, 18 it will be interesting to test the same combination also with rabbit ATG.
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